Skip to navigation Skip to content

Chronic spontaneous urticaria (CSU) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051109

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised omalizumab for patients with severe chronic spontaneous urticaria (CSU).

CSU and listing dates

CSU is a skin condition of persistent hives or welts.

Listing date: omalizumab - 1 September 2017.

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)

Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)

Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)

Written Authority Required Drugs